Is there a benefit to repeating teriparatide therapy in patients with osteogenesis imperfecta and a history of fractures?
Abstract
Current evidence suggests teriparatide can improve bone mineral density in adults with osteogenesis imperfecta, particularly in type I; however, data on the benefits of repeating therapy for fracture reduction are insufficient and more research is needed.
Fields of Study & Subjects
Bone health and osteoporosis research
Connective tissue disorders research
Bone Metabolism and Diseases
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 6 February 2026